Results 91 to 100 of about 15,823 (164)

Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo. [PDF]

Clin Genitourin Cancer
McNeel DG, Eickhoff JC, Perez A, Liu G.
europepmc   +1 more source

Utility of SUVmax on Primary Staging 68Ga‐PSMA PET/CT in Determining Metastatic Status of Prostate Cancer

Journal of Medical Imaging and Radiation Oncology, Volume 70, Issue 5, Page 407-413, August 2026.
ABSTRACT Introduction 68Ga prostate‐specific membrane antigen (PSMA) has been shown to have prognostic value in detecting PSMA expressing metastasis from prostate cancer, but inevitably, there are cases in which suspected metastases demonstrate equivocal uptake.
Geoffrey Liu, Shane Lee, Kabir Ahmad
wiley   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 546-556, August 2026.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

Jaboticaba peel extract limits castration-resistant prostate cancer aggressiveness by counteracting EMT through steroid hormone and TGF-β signaling modulation. [PDF]

J Mol Histol
Schievano FR, de Souza Gianchetto J, Santos FR, Maróstica Júnior MR, Cagnon VHA, Montico F.   +5 more
europepmc   +1 more source

Active surveillance for intermediate risk prostate cancer: the Manitoba Prostate Center experience

BJU International, Volume 138, Issue 2, Page 297-305, August 2026.
Objectives To report long‐term oncological outcomes of men with intermediate‐risk prostate cancer managed with active surveillance at a single centre. Subjects/Patients and Methods We retrospectively analysed a prospectively maintained Manitoba Prostate Centre active surveillance database.
Steven Lu, Connor Roque, Jeff Saranchuk, Ardalan E. Ahmad   +3 more
wiley   +1 more source

Castration Resistance Accelerates Prostate Cancer Kinetics. [PDF]

Prostate
Jonnatan S, Cavka L, De Marzo AM, Denmeade SR, Markowski MC, Antonarakis ES, Trock BJ, Marshall CH, Madan RA, Einstein DJ, Sena LA.   +10 more
europepmc   +1 more source

O‐GlcNAcylation of KAT2A Enhances Bladder Cancer Proliferation by Inhibiting the KAT2A‐TRIM22 Interaction

Cancer Science, Volume 117, Issue 8, Page 2166-2180, August 2026.
Lysine acetyltransferase 2A (KAT2A) is a transcriptional coactivator and a member of the Histone Acetyltransferase (HAT) family. While altered KAT2A activity has been implicated in various cancers, its role in bladder cancer (BLCA) remains poorly understood.
Wenjie Yang, Zhaoheng Jin, Ziyi Li, Weifeng Xu, Yingjie Li, Yueqiang Peng, Jie Dong, Lin Ma, Zhigang Ji   +8 more
wiley   +1 more source

FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate

Histopathology, Volume 89, Issue 2, Page 240-250, August 2026.
FOXA1 is a highly sensitive diagnostic marker for prostate cancer. Besides prostatic adenocarcinoma, it is also expressed in 57%–80% of metastatic or primary prostatic small cell carcinomas, which lose traditional prostatic markers including NKX3.1. Although it is less specific than NKX3.1, it can serve as a valuable adjunct for confirming prostatic ...
Jianping Zhao, Jun Yao, Hossein Hosseini, Ezra Baraban, Ruihe Lin, Charles C. Guo, Lei Huo, Wei Lu, Khaja Khan, Shufang Wang, Luisa Maren Solis Soto, Qingqing Ding   +11 more
wiley   +1 more source

Extracellular vesicles as mediators of prostatic diseases: connecting function to diagnostic and therapeutic applications. [PDF]

Extracell Vesicles Circ Nucl Acids
Bishara J, Morakinyo M, Saini S.
europepmc   +1 more source

[18F]PSMA‐1007 PET–Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer

International Journal of Urology, Volume 33, Issue 8, August 2026.
ABSTRACT Objectives Prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) is a sensitive imaging modality for detecting recurrent prostate cancer following definitive local therapy. However, evidence on 18F‐labeled PSMA tracers in Japanese patients with biochemical recurrence (BCR) remains limited.
Koji Hatano, Tadashi Watabe, Takero Hirata, Masatoshi Konishi, Tomohiro Kanaki, Masaru Tani, Toshiki Oka, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Kazutoshi Fujita, Motohide Uemura, Frederik L. Giesel, Norio Nonomura   +15 more
wiley   +1 more source